Important Product Information

STARLIX (nateglinide) is an oral antidiabetic agent used in the management of type 2 diabetes mellitus or NIDDM. It is rapidly absorbed and stimulates pancreatic insulin within 20 minutes of oral administration. When dosed 3 times a day before meals, there is a rapid rise in plasma insulin, peaking approximately 1 hour after dosing and falling to baseline 4 hours after dosing. The biconvex tablets come in 60 mg and 120 mg units with 60 mg to 360 mg being the dosage range.

Full prescribing information here.

In order to view PDF documents, you must have Adobe® Reader® installed on your computer. If you do not have it, you may download it from the Adobe Web site.

Adobe and Adobe Reader are registered trademarks of Adobe Systems Incorporated.

Important Safety Information

STARLIX is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

STARLIX is contraindicated in patients with a known hypersensitivity to the drug or its inactive ingredients, in patients with type 1 diabetes, or in patients with diabetic ketoacidosis. Patients with ketoacidosis should be treated with insulin.

All oral blood glucose lowering drugs that are absorbed systemically are capable of producing hypoglycemia. Patients should be advised to take STARLIX 1 to 30 minutes prior to eating a meal and to skip the dose if the meal is missed.

STARLIX should be used with caution in patients with moderate to severe liver disease because such patients have not been studied.

The most common adverse events associated with STARLIX vs placebo were upper respiratory infection (10.5% vs 8.1%), back pain (4.0% vs 3.7%), flu symptoms (3.6% vs 2.6%), dizziness (3.6% vs 2.2%), arthropathy (3.3% vs 2.2%), and diarrhea (3.2% vs 3.1%).